CYTH
Price
$1.47
Change
+$0.03 (+2.08%)
Updated
Dec 1, 6:59 PM EST
99 days until earnings call
TEVA
Price
$9.71
Change
-$0.11 (-1.12%)
Updated
Dec 1, 6:59 PM EST
66 days until earnings call
Ad is loading...

CYTH vs TEVA ᐉ Comparison: Which is Better to Invest?

Header iconCYTH vs TEVA Comparison
Open Charts CYTH vs TEVABanner chart's image
Cyclo Therapeutics
Price$1.47
Change+$0.03 (+2.08%)
Volume$13.32K
CapitalizationN/A
Teva Pharmaceutical Industries
Price$9.71
Change-$0.11 (-1.12%)
Volume$3.12M
CapitalizationN/A
View a ticker or compare two or three
CYTH vs TEVA Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
CYTH vs. TEVA commentary
Dec 04, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTH is a StrongBuy and TEVA is a StrongBuy.

COMPARISON
Comparison
Dec 04, 2023
Stock price -- (CYTH: $1.47 vs. TEVA: $9.71)
Brand notoriety: CYTH: Not notable vs. TEVA: Notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: CYTH: 40% vs. TEVA: 74%
Market capitalization -- CYTH: $30.74M vs. TEVA: $11.1B
CYTH [@Pharmaceuticals: Other] is valued at $30.74M. TEVA’s [@Pharmaceuticals: Other] market capitalization is $11.1B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $82.08B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTH’s FA Score shows that 0 FA rating(s) are green whileTEVA’s FA Score has 1 green FA rating(s).

  • CYTH’s FA Score: 0 green, 5 red.
  • TEVA’s FA Score: 1 green, 4 red.
According to our system of comparison, TEVA is a better buy in the long-term than CYTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTH’s TA Score shows that 5 TA indicator(s) are bullish while TEVA’s TA Score has 6 bullish TA indicator(s).

  • CYTH’s TA Score: 5 bullish, 5 bearish.
  • TEVA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, TEVA is a better buy in the short-term than CYTH.

Price Growth

CYTH (@Pharmaceuticals: Other) experienced а +13.95% price change this week, while TEVA (@Pharmaceuticals: Other) price change was +1.68% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.45%. For the same industry, the average monthly price growth was +39.13%, and the average quarterly price growth was -6.49%.

Reported Earning Dates

CYTH is expected to report earnings on Mar 11, 2024.

TEVA is expected to report earnings on Feb 07, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (+3.45% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for CYTH with price predictions.
OPEN
A.I.dvisor published
a Summary for TEVA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
TEVA($11.1B) has a higher market cap than CYTH($30.7M). TEVA YTD gains are higher at: 6.469 vs. CYTH (3.521). TEVA has higher annual earnings (EBITDA): 12M vs. CYTH (-19.36M). TEVA has more cash in the bank: 2.25B vs. CYTH (1.8M). CYTH has less debt than TEVA: CYTH (45.2K) vs TEVA (20.3B). TEVA has higher revenues than CYTH: TEVA (15.3B) vs CYTH (952K).
CYTHTEVACYTH / TEVA
Capitalization30.7M11.1B0%
EBITDA-19.36M12M-161%
Gain YTD3.5216.46954%
P/E RatioN/A22.62-
Revenue952K15.3B0%
Total Cash1.8M2.25B0%
Total Debt45.2K20.3B0%
FUNDAMENTALS RATINGS
CYTH vs TEVA: Fundamental Ratings
CYTH
TEVA
OUTLOOK RATING
1..100
1650
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
80
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
4042
P/E GROWTH RATING
1..100
10015
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYTH's Valuation (64) in the null industry is in the same range as TEVA (80) in the Pharmaceuticals Generic industry. This means that CYTH’s stock grew similarly to TEVA’s over the last 12 months.

CYTH's Profit vs Risk Rating (100) in the null industry is in the same range as TEVA (100) in the Pharmaceuticals Generic industry. This means that CYTH’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's SMR Rating (96) in the Pharmaceuticals Generic industry is in the same range as CYTH (100) in the null industry. This means that TEVA’s stock grew similarly to CYTH’s over the last 12 months.

CYTH's Price Growth Rating (40) in the null industry is in the same range as TEVA (42) in the Pharmaceuticals Generic industry. This means that CYTH’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's P/E Growth Rating (15) in the Pharmaceuticals Generic industry is significantly better than the same rating for CYTH (100) in the null industry. This means that TEVA’s stock grew significantly faster than CYTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTHTEVA
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
74%
Momentum
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
69%
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
65%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 7 days ago
73%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
73%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
56%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TERN5.220.77
+17.30%
Terns Pharmaceuticals
OMIC0.420.03
+6.43%
Singular Genomics Systems
SUM35.550.86
+2.48%
Summit Materials
BLTE42.120.05
+0.12%
Belite Bio
MRVL52.80-2.93
-5.26%
Marvell Technology

CYTH and

Correlation & Price change

A.I.dvisor tells us that CYTH and ACB have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYTH and ACB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTH
1D Price
Change %
CYTH100%
+2.08%
ACB - CYTH
24%
Poorly correlated
+1.80%
RDHL - CYTH
24%
Poorly correlated
-17.00%
CGC - CYTH
22%
Poorly correlated
+10.36%
TEVA - CYTH
21%
Poorly correlated
-1.12%
PTPI - CYTH
21%
Poorly correlated
-8.13%
More

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with VTRS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
-1.12%
VTRS - TEVA
40%
Loosely correlated
+2.07%
ELAN - TEVA
34%
Loosely correlated
+5.26%
PRGO - TEVA
29%
Poorly correlated
+1.44%
PAHC - TEVA
27%
Poorly correlated
+2.92%
EGRX - TEVA
27%
Poorly correlated
+4.75%
More